The Effect of Biologics in the Treatment of Multisystem Inflammatory Syndrome in Children (Mis-C) : A Single-Center Propensity-Score-Matched Study
Multisystem inflammatory syndrome in children (MIS-C) is a serious condition characterized by excessive inflammation that can arise as a complication of SARS-CoV-2 infection in children. While our understanding of COVID-19 and MIS-C has been advancing, there is still uncertainty regarding the optimal treatment for MIS-C. In this study, we aimed to compare the clinical and laboratory outcomes of MIS-C patients treated with IVIG plus corticosteroids (CS) to those treated with IVIG plus CS and an additional biologic drug. We used the propensity score (PS)-matching method to assess the relationships between initial treatment and outcomes. The primary outcome was a left ventricular ejection fraction of less than 55% on day 2 or beyond and/or the requirement of inotrope support on day 2 or beyond. We included 79 MIS-C patients (median age 8.51 years, 33 boys) followed in our center. Among them, 50 children (25 in each group) were allocated to the PS-matched cohort sample. The primary outcome was observed in none of the patients in the IVIG and CS group, while it occurred in eight patients in the IVIG plus CS and biologic group (p = 0.04). MIS-C is a disorder that may progress rapidly and calls for extensive care. For definitive recommendations, further studies, including randomized control trials, are required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Children (Basel, Switzerland) - 10(2023), 6 vom: 11. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Basaran, Ozge [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biologic |
|---|
| Anmerkungen: |
Date Revised 01.07.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/children10061045 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358725879 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358725879 | ||
| 003 | DE-627 | ||
| 005 | 20231226075344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/children10061045 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358725879 | ||
| 035 | |a (NLM)37371276 | ||
| 035 | |a (PII)1045 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Basaran, Ozge |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Effect of Biologics in the Treatment of Multisystem Inflammatory Syndrome in Children (Mis-C) |b A Single-Center Propensity-Score-Matched Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Multisystem inflammatory syndrome in children (MIS-C) is a serious condition characterized by excessive inflammation that can arise as a complication of SARS-CoV-2 infection in children. While our understanding of COVID-19 and MIS-C has been advancing, there is still uncertainty regarding the optimal treatment for MIS-C. In this study, we aimed to compare the clinical and laboratory outcomes of MIS-C patients treated with IVIG plus corticosteroids (CS) to those treated with IVIG plus CS and an additional biologic drug. We used the propensity score (PS)-matching method to assess the relationships between initial treatment and outcomes. The primary outcome was a left ventricular ejection fraction of less than 55% on day 2 or beyond and/or the requirement of inotrope support on day 2 or beyond. We included 79 MIS-C patients (median age 8.51 years, 33 boys) followed in our center. Among them, 50 children (25 in each group) were allocated to the PS-matched cohort sample. The primary outcome was observed in none of the patients in the IVIG and CS group, while it occurred in eight patients in the IVIG plus CS and biologic group (p = 0.04). MIS-C is a disorder that may progress rapidly and calls for extensive care. For definitive recommendations, further studies, including randomized control trials, are required | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biologic | |
| 650 | 4 | |a children | |
| 650 | 4 | |a comparison | |
| 650 | 4 | |a management | |
| 650 | 4 | |a multisystem inflammatory syndrome in children (MIS-C) | |
| 650 | 4 | |a outcomes | |
| 700 | 1 | |a Batu, Ezgi Deniz |e verfasserin |4 aut | |
| 700 | 1 | |a Kaya Akca, Ummusen |e verfasserin |4 aut | |
| 700 | 1 | |a Atalay, Erdal |e verfasserin |4 aut | |
| 700 | 1 | |a Kasap Cuceoglu, Muserref |e verfasserin |4 aut | |
| 700 | 1 | |a Sener, Seher |e verfasserin |4 aut | |
| 700 | 1 | |a Balık, Zeynep |e verfasserin |4 aut | |
| 700 | 1 | |a Karabulut, Erdem |e verfasserin |4 aut | |
| 700 | 1 | |a Kesici, Selman |e verfasserin |4 aut | |
| 700 | 1 | |a Karagoz, Tevfik |e verfasserin |4 aut | |
| 700 | 1 | |a Ozsurekci, Yasemin |e verfasserin |4 aut | |
| 700 | 1 | |a Bilginer, Yelda |e verfasserin |4 aut | |
| 700 | 1 | |a Cengiz, Ali Bulent |e verfasserin |4 aut | |
| 700 | 1 | |a Ozen, Seza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Children (Basel, Switzerland) |d 2014 |g 10(2023), 6 vom: 11. Juni |w (DE-627)NLM246337737 |x 2227-9067 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:6 |g day:11 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/children10061045 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 6 |b 11 |c 06 | ||